Critical Comparison: KalVista Pharmaceuticals (KALV) and Strongbridge Biopharma PLC (SBBP)
KalVista Pharmaceuticals (NASDAQ: KALV) and Strongbridge Biopharma PLC (NASDAQ:SBBP) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, profitability, earnings, analyst recommendations and risk.
Valuation & Earnings
This table compares KalVista Pharmaceuticals and Strongbridge Biopharma PLC’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|KalVista Pharmaceuticals||$1.50 million||57.50||-$15.90 million||N/A||N/A|
|Strongbridge Biopharma PLC||$1.53 million||144.34||-$39.43 million||($2.78)||-2.25|
KalVista Pharmaceuticals has higher revenue, but lower earnings than Strongbridge Biopharma PLC.
This table compares KalVista Pharmaceuticals and Strongbridge Biopharma PLC’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Strongbridge Biopharma PLC||N/A||-83.83%||-34.77%|
Volatility and Risk
KalVista Pharmaceuticals has a beta of 2.52, indicating that its share price is 152% more volatile than the S&P 500. Comparatively, Strongbridge Biopharma PLC has a beta of 2.72, indicating that its share price is 172% more volatile than the S&P 500.
This is a summary of recent recommendations for KalVista Pharmaceuticals and Strongbridge Biopharma PLC, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Strongbridge Biopharma PLC||0||0||3||0||3.00|
KalVista Pharmaceuticals presently has a consensus price target of $18.00, indicating a potential upside of 102.70%. Strongbridge Biopharma PLC has a consensus price target of $13.33, indicating a potential upside of 113.33%. Given Strongbridge Biopharma PLC’s higher probable upside, analysts plainly believe Strongbridge Biopharma PLC is more favorable than KalVista Pharmaceuticals.
Insider and Institutional Ownership
75.7% of KalVista Pharmaceuticals shares are held by institutional investors. Comparatively, 63.7% of Strongbridge Biopharma PLC shares are held by institutional investors. 49.1% of KalVista Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Strongbridge Biopharma PLC beats KalVista Pharmaceuticals on 7 of the 11 factors compared between the two stocks.
KalVista Pharmaceuticals Company Profile
KalVista Pharmaceuticals, Inc., formerly Carbylan Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME). The Company is developing a plasma kallikrein inhibitor, which is administered directly into the eye. The Company is engaged in advancing several product candidates developed from its portfolio into early clinical trials. The Company is progressing additional oral candidates towards regulatory preclinical studies. The Company’s HAE product candidate, KVD818, is an inhibitor of plasma kallikrein. The Company has initiated clinical testing of KVD818 in a Phase I clinical trial. It has completed an open-label single ascending dose Phase I trial in DME patients with KVD001.
Strongbridge Biopharma PLC Company Profile
Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company’s commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis. The United States Food and Drug Administration (FDA) has granted orphan drug designation for KEVEYIS. The Company has a clinical-stage pipeline of therapies for endocrine diseases. The Company’s lead compounds include COR-003 (levoketoconazole), a cortisol synthesis inhibitor, and COR-005 (veldoreotide), a somatostatin analog (SSA). The Company is studying COR-003 for the treatment of endogenous Cushing’s syndrome. It is investigating COR-005 for the treatment of acromegaly. Both COR-003 and COR-005 have received orphan designation from the FDA and the European Medicines Agency (EMA).
Receive News & Stock Ratings for KalVista Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KalVista Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.